

Product Portfolio

2018/2019



since 1986


Pharmazac

Product List | 2018 / 2019

Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
Rivaroxaban	F.c. tablets	2.5mg 10mg 15mg 20mg	Oral anticoagulant	Q4 2018
Sitagliptin hydrochloride	F.c. tablets	25mg 50mg 100mg	Oral antidiabetic	Q2 2019
Sitagliptin hydrochloride + Metformin	F.c. tablets	50mg+500mg 50mg+850mg 50mg+1000mg	Oral antidiabetic	Q2 2019
Micafungin	Powder for solution for infusion	100mg/10ml 50mg/10ml	Antifungal	Q3 2019
Caspofungin	Powder for solution for infusion	50mg/10ml 70mg/10ml	Antifungal	EU registered
Vortioxetine	F.c. tablets	5mg 10mg 20mg	Antidepressant	Q4 2019
Apixaban	F.c. tablets	2.5mg 5mg	Oral anticoagulant	Q1 2020
Ticagrelor	F.c. tablets	60mg 90mg	Platelet aggregation inhibitor	Q4 2019

Products which are subject to patent protection are currently not offered or made available in countries where patents are in force. No orders or deliveries, prior to patent expiry are possible.

Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
Rosuvastatin + Ezetimibe	Tablets	5mg+10mg 10mg+10mg 20mg+10mg 40mg+10mg	Cholesterol and triglyceride regulator	Available
Cholecalciferol	Hard gel capsules	10,000 IU 25,000 IU	Treatment or prevention of vitamin D deficiency	Available
Zoledronic acid	Concetrate for solution for infusion in glass vial	4mg/5ml 5mg/100ml	Prevention skeletal fractures & treatment hypercalcemia	EU registered
Venlafaxine SR	Capsules	75mg 150mg	Oral antidepressant	EU registered
Mirabegron	Prolonged released f.c. tablets	25mg 50mg	Urinary antispasmodic	Under development
Dapagliflozin	F.c. tablets	10mg	Oral antidiabetic	Under development
Prednisolone	Oral solution	1 mg/ml 10 mg/ml	Corticosteroids for systemic use	Q2 2019
Calcium Folate	Solution for injection	200mg/20ml	Antidote against folic acid antagonists Detoxifying agent for antineoplastic treatment	EU registered

Products which are subject to patent protection are currently not offered or made available in countries where patents are in force. No orders or deliveries, prior to patent expiry are possible.

Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
Valsartan	F.c. tablets	80mg 160mg 320mg	Angiotensin-II antagonist	EU registered
Valsartan + Hydrochlorothiazide	F.c. tablets	80mg+12,5mg 160mg+12,5mg 160mg+25mg 320mg+12,5mg 320mg+25mg	Angiotensin-II antagonist & diuretic combination	EU registered
Olanzapine	Orodispersible tablets	5mg 10mg 15mg 20mg	Antipsychotic	EU registered
Ferrous Gluconate	Effervescent tablets Powder for oral solution	695MG (80.5 mgFe ⁺⁺)/Tab 300MG (37,5mg Fe ⁺⁺)/Sachet	Iron deficiency	EU registered
Magnesium Citrate + Magnesium Aspartate	Effervescent tablets	243mg (Mg ²⁺)	Mineral supplement	Q4 2018
Petasites Hybridus	Liquid hard gelatine capsules	70,4mg	Food supplement	EU registered

Products which are subject to patent protection are currently not offered or made available in countries where patents are in force. No orders or deliveries, prior to patent expiry are possible.

Product Portfolio

2018 / 2019



31 Naousis Str. - 104 47 Athens - Greece
Tel.: +30 210 3418889-97
Fax: +30 210 8661262
e-mail: pharmazac@pharmazac.com



www.pharmazac.com